IMRX
ImmuneeringDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
Successful clinical readouts or a strategic partnership could re-rate the stock materially above the current anchor.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +17.5.
What can break
Clinical setbacks or a dilutive financing would likely push the share price significantly below the anchor.
Momentum
7
Value
41
Sentiment
97
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.35 · Bull $9.00 · Bear $4.00
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-09 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-17 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $17.17
Why
Momentum7 · Δ7d -8.3
Value41 · Δ7d -0.1
Sentiment97 · Δ7d +17.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
7
34% active weight
Current posture
7d trendSoftening
Δ7d
-8.3
Δ21d
-22.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.1
Sentiment
97
33% active weight
Current posture
7d trendImproving
Δ7d
+17.5
Δ21d
+33.0
Why this grade
Composite grade D. Momentum 7.3 / Value 41.0 / Sentiment 96.8
Fundamentals (TTM)As of 2026-06-09
Fundamentals (TTM)
As of 2026-06-09
Market Cap
$260.73M
Beta
0.47
Shares Out
64.57M
P/E (TTM) · Derived
-2.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.87
Rev YoY
-
EPS YoY
+22.9%
Gross Margin
-
Op Margin
-
Net Debt
-$36.14M
Current Ratio
24.00
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology